MedPath

Shanghai Changhai Hospital

🇨🇳China
Ownership
Private
Employees
-
Market Cap
-
Website

Clinical Trials

323

Active:8
Completed:90

Trial Phases

6 Phases

Early Phase 1:5
Phase 1:15
Phase 2:17
+3 more phases

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (210 trials with phase data)• Click on a phase to view related trials

Not Applicable
150 (71.4%)
Phase 2
17 (8.1%)
Phase 1
15 (7.1%)
Phase 4
14 (6.7%)
Phase 3
9 (4.3%)
Early Phase 1
5 (2.4%)

Artificial Intelligence-powered Low-Dose Computed Tomography for Screening of Pancreatic Cancer

Recruiting
Conditions
Pancreatic Cancer
Intraductal Papillary Mucinous Neoplasm
High-grade Pancreatic Intraepithelial Neoplasia
PDAC - Pancreatic Ductal Adenocarcinoma
Mucinous Cystic Neoplasm
First Posted Date
2025-08-12
Last Posted Date
2025-08-12
Lead Sponsor
Changhai Hospital
Target Recruit Count
400000
Registration Number
NCT07117045
Locations
🇨🇳

Meinian Onehealth Healthcare Holdings Co., Ltd, Shanghai, Shanghai, China

🇨🇳

Ruici Medical Examination Institution, Shanghai, Shanghai, China

🇨🇳

Changhai Hospital, Shanghai, Shanghai, China

and more 2 locations

Perioperative Blood Transfusion and Increased One-year Mortality

Completed
Conditions
Mortality, Perioperative Blood Transfusion, Propensity Score, Retrospective Study, Surgery
First Posted Date
2025-07-30
Last Posted Date
2025-07-30
Lead Sponsor
Changhai Hospital
Target Recruit Count
97443
Registration Number
NCT07094295

Comparison of the Sensitivity of pCLE and Pathological Biopsy Before ESD

Not yet recruiting
Conditions
Gastric Cancer (Diagnosis)
Gastric High-grade Intraepithelial Neoplasia
Gastric Low-grade Intraepithelial Neoplasia
Gastritis
First Posted Date
2025-07-28
Last Posted Date
2025-07-28
Lead Sponsor
Changhai Hospital
Target Recruit Count
169
Registration Number
NCT07088744
Locations
🇨🇳

Guangxi Zhuang Autonomous Region People's Hospital, Nanning, Guangxi, China

🇨🇳

Northern Theater Command Hospital, Shenyang, Liaoning, China

🇨🇳

West China Hospital of Sichuan University, Chengdu, Sichuan, China

and more 1 locations

Low-Dose vs Standard-Dose Indomethacin for Preventing Post-ERCP Pancreatitis

Not Applicable
Not yet recruiting
Conditions
Post-ERCP Pancreatitis
Interventions
Drug: low dose indomethacin
First Posted Date
2025-07-28
Last Posted Date
2025-07-28
Lead Sponsor
Changhai Hospital
Target Recruit Count
1366
Registration Number
NCT07088757
Locations
🇨🇳

Changhai Hospital, Shanghai, China

🇨🇳

Ruijin Hospital, Shanghai, China

🇨🇳

Shanghai General Hospital, Shanghai, China

and more 9 locations

Endotherapy and/or Extracorporeal Shockwave Lithotripsy for Painless Chronic Pancreatitis

Not Applicable
Recruiting
Conditions
Painless Chronic Pancreatitis
Interventions
Behavioral: Lifestyle modifications
Drug: Pancreatic enzyme (Pancreatin Enteric-coated Capsules or Oryz-Aspergillus Enzyme and Pancreatin Table), antidiabetic medicine(Acarbose , Metformin, Glimepirde Tablets, Insulin)
Procedure: Endoscopic Retrograde Cholangiopancreatography (ERCP) and/or Extracorporeal Shockwave Lithotripsy (ESWL)
First Posted Date
2025-07-20
Last Posted Date
2025-08-06
Lead Sponsor
Changhai Hospital
Target Recruit Count
126
Registration Number
NCT07074379
Locations
🇨🇳

Changhai Hospital, Shanghai, Shanghai, China

  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 64
  • Next

News

PROTECT-MT Trial Suggests Worse Outcomes with Balloon Guide Catheters in Stroke Thrombectomy

The PROTECT-MT trial, a randomized controlled study, indicated that stroke thrombectomy using balloon guide catheters (BGCs) may lead to inferior functional outcomes compared to conventional guide catheters.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.